Trial Profile
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC 704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Carboplatin; Carboplatin; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer
- Focus Registrational; Therapeutic Use
- 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 17 Apr 2019 Results evaluating four different treatment regimens(paclitaxel-carboplatin, oxaliplatin-capecitabine, paclitaxel-carboplatin-bevacizumab, or oxaliplatin-capecitabine-bevacizumab) for advanced-stage mucinous epithelial ovarian cancerpublished in the Gynecologic Oncology
- 02 Jun 2015 According to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology, due to poor accrual trial was discontinued.